The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Navigating escalation and de-escalation strategies in immunotherapy for NSCLC
Nicolas Girard, MD, Institut Curie, Paris, France, highlights the evolving trends in first-line treatment for non-small cell lung cancer (NSCLC). Combination therapies incorporating checkpoint inhibitors, antibody-drug conjugates (ADCs), and bispecific antibodies are aimed at improving progression-free and overall survival. De-escalation approaches like the NIVAHL study (NCT03004833), which reduces pembrolizumab doses, additionally show no loss in efficacy. This dual approach underscores the need for personalized immunotherapy, potentially driven by biomarkers, to optimize treatment for individual patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
